Fed Regist. 1993 Apr 1;58(61):17093-4.
The Food and Drug Administration (FDA) is amending the regulations for delegations of authority relating to the approval of new drug applications (NDA's), abbreviated new drug applications (ANDA's), and their supplements to add the Deputy Director (Medical and Scientific Affairs), Center for Drug Evaluation and Research (CDER), to the list of officials authorized to approve certain NDA's, ANDA's, and their supplements for drugs for human use. In addition, FDA is adding authority to approve applications submitted under section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (the act) (505(b)(2) applications) to these officials. These authorities were given to FDA under section 505 of the act.
美国食品药品监督管理局(FDA)正在修订有关新药申请(NDA)、简略新药申请(ANDA)及其补充申请审批的授权规定,将药品评价和研究中心(CDER)副主任(医学和科学事务)列入被授权批准某些用于人类药品的NDA、ANDA及其补充申请的官员名单。此外,FDA正在赋予这些官员批准根据《联邦食品、药品和化妆品法案》(该法案)第505(b)(2)条提交的申请(505(b)(2)申请)的权力。这些权力是根据该法案第505条赋予FDA的。